The somatoform disorders are a group of psychological disorders in which
a patient experiences physical symptoms that are inconsistent with or cannot be
fully explained by any underlying general medical or neurologic condition. They
often lead to significant impairment in the
quality of life of patients and their families with high levels of subsequent
stress and strains. And to identify the somatoform disorders in children and adolescents in German, a
Screening for Somatoform Disorders in Children and Adolescents (SOMS-CA) was
developed based on the Screening for Somatoform Disorders (SOMS-2).
The aim of this study was to investigate to
what extent the SOMS-CA can differentiate significantly between children and
adolescents with clinically diagnosed somatoform disorders and a control group
and whether the SOMS-CA is superior to the GSCL-C (Giessen
Subjective Complaint List for Children).
30 patients (11 - 17 years) with somatoform
disorders and a control group (n = 31) were examined with the SOMS-CA (N = 61).
The results from the SOMS-CA in both groups were compared with one another by
means of a contingency analysis (chi-square test). The sensitivity and
specificity were calculated and an optimal cut-off value was determined
(Receiver Operating Characteristic curve (ROC-curve) analysis). A comparison
analysis of the ROC-curves of the SOMS-CA and the GSCL-C followed.
The sum score of complaints in the patients
was significantly higher than that in the control group. The ROC-curve for the
SOMS-CA demonstrated its excellent ability to differentiate between the two
groups with an AUC (area under the curve) = 0.983 (SE = 0.14; N = 61). The
sensitivity was 97.6%, the specificity 96.8%. In comparison to the AUC of the
GSCL-C, the SOMS-CA showed a much higher result. The SOMS-CA successfully
identified patients with somatoform disorders from a paediatric population and
differentiates from healthy test subjects. A comparison to the GSCL-C showed a
considerable superiority of the SOMS-CA.
In summary, the SOMS-CA successfully identifies patients with somatoform disorders
from a paediatric population and differentiates from healthy test subjects. A
comparison to the GSCL-C shows a considerable superiority of the SOMS-CA.
Further studies on the validity of the SOMS-CA are in process, in particular
the SOMS-CA as a screening for patients with other psychiatric disorders and
for patients with chronic somatic diseases.
Article by S.
Winter, et al, from Charité-Universitatsmedizin, Berlin, Germany.
Full access: http://suo.im/4TnCyV
评论
发表评论